By Associate Professor Deborah Cromer

Preprints

Stadler E; Burgess M; Schlub T; Chai KL; McQuilten Z; Wood E; Polizzotto M; Kent S; Cromer D; Davenport M; Khoury D, 2022, Monoclonal antibody levels and protection from COVID-19, http://dx.doi.org/10.1101/2022.11.22.22282199

Cromer D; Steain M; Reynaldi A; Schlub T; Sasson S; Kent S; Khoury D; Davenport MP, 2022, Neutralising antibodies predict protection from severe COVID-19, http://dx.doi.org/10.1101/2022.06.09.22275942

Khoury D; Docken S; Subbarao K; Kent S; Davenport M; Cromer D, 2022, Predicting the efficacy of variant-modified COVID-19 vaccine boosters, http://dx.doi.org/10.1101/2022.08.25.22279237

Stadler E; Cromer D; Mehra S; Adekunle A; Flegg J; Anstey N; Watson J; Chu C; Mueller I; Robinson L; Schlub T; Davenport M; Khoury D, 2022, Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population, http://dx.doi.org/10.1101/2022.05.18.22275180

Aggarwal A; Stella A; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Lenthall H; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fitcher C; Hoppe AC; Munier CML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.21203/rs.3.rs-1207364/v1

Khoury D; Steain M; Triccas J; Sigal A; Davenport M; Cromer D, 2021, A meta-analysis of Early Results to predict Vaccine efficacy against Omicron, http://dx.doi.org/10.1101/2021.12.13.21267748

Koutsakos M; Lee WS; Reynaldi A; Tan H-X; Gare G; Kinsella P; Liew KC; Williamson D; Kent H; Stadler E; Cromer D; Khoury D; Wheatley A; Juno J; Davenport M; Kent S, 2021, Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection, http://dx.doi.org/10.1101/2021.12.23.21268285

Cromer D; Reynaldi A; Steain M; Triccas J; Davenport M; Khoury D, 2021, Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial, http://dx.doi.org/10.1101/2021.06.29.21259504

Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP, 2021, SARS-CoV-2 variants: levels of neutralisation required for protective immunity, http://dx.doi.org/10.1101/2021.08.11.21261876

Khoury DS; Cromer D; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Subbarao K; Kent SJ; Triccas JA; Davenport MP, 2021, What level of neutralising antibody protects from COVID-19?, http://dx.doi.org/10.1101/2021.03.09.21252641

Lee WS; Selva KJ; Davis S; Wines B; Reynaldi A; Esterbauer R; Kelly H; Haycroft E; Tan H-X; Juno J; Wheatley A; Hogarth M; Cromer D; Davenport M; Chung A; Kent S, 2020, Decay of Fc-dependent antibody functions after mild to moderate COVID-19, http://dx.doi.org/10.1101/2020.12.13.20248143

Price D; Shearer F; Meehan M; McBryde E; Moss R; Golding N; Conway E; Dawson P; Cromer D; Wood J; Abbott S; McVernon J; McCaw J, 2020, Early analysis of the Australian COVID-19 epidemic, http://dx.doi.org/10.1101/2020.04.25.20080127

Wheatley A; Juno J; Wang J; Selva K; Reynaldi A; Tan H-X; Shi Lee W; Wragg K; Kelly H; Esterbauer R; Davis S; Kent H; Mordant F; Schlub T; Gordon D; Khoury D; Subbarao K; Cromer D; Gordon T; Chung A; Davenport M; Kent S, 2020, Evolution of immunity to SARS-CoV-2, http://dx.doi.org/10.1101/2020.09.09.20191205

Cao P; Klonis N; Zaloumis S; Khoury DS; Cromer D; Davenport MP; Tilley L; Simpson JA; McCaw JM, 2017, A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection, http://dx.doi.org/10.48550/arxiv.1701.05302

Back to profile page